Author

K. M. Bond

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 2 Assay:imaging· 2 Approach:statistical model· 2 Research Focus:cell type annotation· 1 Research Focus:protein structure prediction· 1 Research Focus:spatial domain detection· 1

Frequent Co-Authors

G. De Leon· 2 shared K. R. Swanson· 2 shared K. W. Singleton· 2 shared L. S. Hu· 2 shared M. M. Mrugala· 2 shared A. B. Porter· 1 shared A. Hawkins-Daarud· 1 shared A. R. A. Anderson· 1 shared

Activity by Year

2019-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 41 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

G. De Leon

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Mapping multiregional imaging-localized biopsies to MRI habitats reveals biologically significant glioma tissue states and associated patterns of cohabitating cellular subpopulations

L. Curtin, K. M. Bond, P. R. Jackson, A. Hawkins-Daarud, S. Velez, N. Shakir, J. C. Urcuyo, G. De Leon, K. W. Singleton, J. M. Langworthy, K. Clark-Swanson, Y. Lassiter-Morris, L. Paulson, C. Sereduk, C. Krishna, , K. R. Swanson

The paper maps MRI-localized glioma biopsies to MRI habitats, identifying transcriptional tissue states and their association with cellular subpopulations and MRI features.

bioRxiv · Mar 23, 2022 · PreprintCancer Biology

Days Gained Response Discriminates Treatment Response in Patients with Recurrent Glioblastoma Receiving Bevacizumab-based Therapies

K. W. Singleton, A. B. Porter, L. S. Hu, S. K. Johnston, K. M. Bond, C. R. Rickertsen, G. De Leon, S. A. Whitmire, K. R. Clark-Swanson, M. M. Mrugala, K. R. Swanson

This study evaluates Days Gained (DG) as a metric for assessing treatment response in recurrent glioblastoma patients receiving bevacizumab-based therapies, showing its prognostic significance for survival outcomes.

bioRxiv · Aug 30, 2019Cancer Biology